TY - JOUR
T1 - The potential impact of nanomedicine on COVID-19-induced thrombosis
AU - Russell, Peije
AU - Esser, Lars
AU - Hagemeyer, Christoph E.
AU - Voelcker, Nicolas H.
N1 - Funding Information:
P.R. thanks the Australian Institute of Nuclear Science and Engineering (AINSE) for a postgraduate research award. L.E. thanks AINSE for an early-career research grant and the CASS Foundation for a science/medicine grant (10021). C.E.H. thanks the National Health and Medical Research Council (NHMRC) of Australia for a Senior Research Fellowship (award number GNT1154270).
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2023/1
Y1 - 2023/1
N2 - Extensive reports of pulmonary embolisms, ischaemic stroke and myocardial infarctions caused by coronavirus disease 2019 (COVID-19), as well as a significantly increased long-term risk of cardiovascular diseases in COVID-19 survivors, have highlighted severe deficiencies in our understanding of thromboinflammation and the need for new therapeutic options. Due to the complexity of the immunothrombosis pathophysiology, the efficacy of treatment with conventional anti-thrombotic medication is questioned. Thrombolytics do appear efficacious, but are hindered by severe bleeding risks, limiting their use. Nanomedicine can have profound impact in this context, protecting delicate (bio)pharmaceuticals from degradation en route and enabling delivery in a targeted and on demand manner. We provide an overview of the most promising nanocarrier systems and design strategies that may be adapted to develop nanomedicine for COVID-19-induced thromboinflammation, including dual-therapeutic approaches with antiviral and immunosuppressants. Resultant targeted and side-effect-free treatment may aid greatly in the fight against the ongoing COVID-19 pandemic.
AB - Extensive reports of pulmonary embolisms, ischaemic stroke and myocardial infarctions caused by coronavirus disease 2019 (COVID-19), as well as a significantly increased long-term risk of cardiovascular diseases in COVID-19 survivors, have highlighted severe deficiencies in our understanding of thromboinflammation and the need for new therapeutic options. Due to the complexity of the immunothrombosis pathophysiology, the efficacy of treatment with conventional anti-thrombotic medication is questioned. Thrombolytics do appear efficacious, but are hindered by severe bleeding risks, limiting their use. Nanomedicine can have profound impact in this context, protecting delicate (bio)pharmaceuticals from degradation en route and enabling delivery in a targeted and on demand manner. We provide an overview of the most promising nanocarrier systems and design strategies that may be adapted to develop nanomedicine for COVID-19-induced thromboinflammation, including dual-therapeutic approaches with antiviral and immunosuppressants. Resultant targeted and side-effect-free treatment may aid greatly in the fight against the ongoing COVID-19 pandemic.
UR - http://www.scopus.com/inward/record.url?scp=85144261693&partnerID=8YFLogxK
U2 - 10.1038/s41565-022-01270-6
DO - 10.1038/s41565-022-01270-6
M3 - Review Article
C2 - 36536042
AN - SCOPUS:85144261693
SN - 1748-3387
VL - 18
SP - 11
EP - 22
JO - Nature Nanotechnology
JF - Nature Nanotechnology
IS - 1
ER -
